Myelodysplastic syndrome, osteoporosis and medication-related osteonecrosis of the jaw: a case report
Introduction: Medication-related osteonecrosis of the jaw is a frequent collateral effect found in patients under antiresorptive treatments. Malignancies such as multiple myeloma, breast and prostate cancer as well as bone-metabolic disorders such as osteoporosis, lead the indications for these anti...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional Cba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2020
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/30318 |
| Aporte de: |
| id |
I10-R10-article-30318 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-10 |
| container_title_str |
Revistas de la UNC |
| language |
Español |
| format |
Artículo revista |
| topic |
bisphosphonate-associated osteonecrosis of the jaw osteoporosis myelodysplastic syndromes osteonecrosis de los maxilares asociada a difosfonatos osteoporosis síndromes mielodisplásicos osteonecrose da arcada osseodentária associada a difosfonatos osteoporose síndrome mielodisplásica |
| spellingShingle |
bisphosphonate-associated osteonecrosis of the jaw osteoporosis myelodysplastic syndromes osteonecrosis de los maxilares asociada a difosfonatos osteoporosis síndromes mielodisplásicos osteonecrose da arcada osseodentária associada a difosfonatos osteoporose síndrome mielodisplásica Leonardi, Nicolás Garola , Federico Gilligan, Gerardo Piemonte , Eduardo Cappella, Fiamma Panico, René Myelodysplastic syndrome, osteoporosis and medication-related osteonecrosis of the jaw: a case report |
| topic_facet |
bisphosphonate-associated osteonecrosis of the jaw osteoporosis myelodysplastic syndromes osteonecrosis de los maxilares asociada a difosfonatos osteoporosis síndromes mielodisplásicos osteonecrose da arcada osseodentária associada a difosfonatos osteoporose síndrome mielodisplásica |
| author |
Leonardi, Nicolás Garola , Federico Gilligan, Gerardo Piemonte , Eduardo Cappella, Fiamma Panico, René |
| author_facet |
Leonardi, Nicolás Garola , Federico Gilligan, Gerardo Piemonte , Eduardo Cappella, Fiamma Panico, René |
| author_sort |
Leonardi, Nicolás |
| title |
Myelodysplastic syndrome, osteoporosis and medication-related osteonecrosis of the jaw: a case report |
| title_short |
Myelodysplastic syndrome, osteoporosis and medication-related osteonecrosis of the jaw: a case report |
| title_full |
Myelodysplastic syndrome, osteoporosis and medication-related osteonecrosis of the jaw: a case report |
| title_fullStr |
Myelodysplastic syndrome, osteoporosis and medication-related osteonecrosis of the jaw: a case report |
| title_full_unstemmed |
Myelodysplastic syndrome, osteoporosis and medication-related osteonecrosis of the jaw: a case report |
| title_sort |
myelodysplastic syndrome, osteoporosis and medication-related osteonecrosis of the jaw: a case report |
| description |
Introduction: Medication-related osteonecrosis of the jaw is a frequent collateral effect found in patients under antiresorptive treatments. Malignancies such as multiple myeloma, breast and prostate cancer as well as bone-metabolic disorders such as osteoporosis, lead the indications for these antiresorptive therapies. Even with a low frequency, myelodysplastic syndromes are also entities that have previously been associated with the development of jaw osteonecrosis. Objective: the aim of this study is to present a case of a 78-year-old male patient with myelodysplastic syndrome and secondary osteoporosis, treated with high-dose Zoledronic Acid and who developed a clinical scenario compatible with medication-related osteonecrosis of the jaw during its evolution. Methodology: the case was recorded and treated in the Oral Medicine Department, Facultad de Odontología, Universidad Nacional de Córdoba, during a two-years period with a partial resolution, which recurred fourteen months later, where finally therapeutic success was achieved through a conservative management. Conclusion: Due to the increasingly use of antiresorptive drugs, the development of jaw osteonecrosis is possible associated with less frequent pathologies, such as myelodysplastic syndrome. Treatment success in these patients depends on interdisciplinary management and a rigorous clinical, medical and dental follow-up. |
| publisher |
Universidad Nacional Cba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2020 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/30318 |
| work_keys_str_mv |
AT leonardinicolas myelodysplasticsyndromeosteoporosisandmedicationrelatedosteonecrosisofthejawacasereport AT garolafederico myelodysplasticsyndromeosteoporosisandmedicationrelatedosteonecrosisofthejawacasereport AT gilligangerardo myelodysplasticsyndromeosteoporosisandmedicationrelatedosteonecrosisofthejawacasereport AT piemonteeduardo myelodysplasticsyndromeosteoporosisandmedicationrelatedosteonecrosisofthejawacasereport AT cappellafiamma myelodysplasticsyndromeosteoporosisandmedicationrelatedosteonecrosisofthejawacasereport AT panicorene myelodysplasticsyndromeosteoporosisandmedicationrelatedosteonecrosisofthejawacasereport AT leonardinicolas sindromemielodisplasicoosteoporosisyosteonecrosismaxilarasociadaamedicamentosantirresortivosreportedeuncaso AT garolafederico sindromemielodisplasicoosteoporosisyosteonecrosismaxilarasociadaamedicamentosantirresortivosreportedeuncaso AT gilligangerardo sindromemielodisplasicoosteoporosisyosteonecrosismaxilarasociadaamedicamentosantirresortivosreportedeuncaso AT piemonteeduardo sindromemielodisplasicoosteoporosisyosteonecrosismaxilarasociadaamedicamentosantirresortivosreportedeuncaso AT cappellafiamma sindromemielodisplasicoosteoporosisyosteonecrosismaxilarasociadaamedicamentosantirresortivosreportedeuncaso AT panicorene sindromemielodisplasicoosteoporosisyosteonecrosismaxilarasociadaamedicamentosantirresortivosreportedeuncaso AT leonardinicolas sindromemielodisplasicaosteoporoseeosteonecrosedosmaxilaresassociadaaousodedrogasantireabsortivasrelatodecaso AT garolafederico sindromemielodisplasicaosteoporoseeosteonecrosedosmaxilaresassociadaaousodedrogasantireabsortivasrelatodecaso AT gilligangerardo sindromemielodisplasicaosteoporoseeosteonecrosedosmaxilaresassociadaaousodedrogasantireabsortivasrelatodecaso AT piemonteeduardo sindromemielodisplasicaosteoporoseeosteonecrosedosmaxilaresassociadaaousodedrogasantireabsortivasrelatodecaso AT cappellafiamma sindromemielodisplasicaosteoporoseeosteonecrosedosmaxilaresassociadaaousodedrogasantireabsortivasrelatodecaso AT panicorene sindromemielodisplasicaosteoporoseeosteonecrosedosmaxilaresassociadaaousodedrogasantireabsortivasrelatodecaso |
| first_indexed |
2022-08-20T01:27:35Z |
| last_indexed |
2022-08-20T01:27:35Z |
| _version_ |
1770719080037220352 |
| spelling |
I10-R10-article-303182021-07-15T20:12:32Z Myelodysplastic syndrome, osteoporosis and medication-related osteonecrosis of the jaw: a case report Síndrome mielodisplásico, osteoporosis y osteonecrosis maxilar asociada a medicamentos antirresortivos: reporte de un caso Síndrome mielodisplásica, osteoporose e osteonecrose dos maxilares associada ao uso de drogas anti-reabsortivas: relato de caso Leonardi, Nicolás Garola , Federico Gilligan, Gerardo Piemonte , Eduardo Cappella, Fiamma Panico, René bisphosphonate-associated osteonecrosis of the jaw osteoporosis myelodysplastic syndromes osteonecrosis de los maxilares asociada a difosfonatos osteoporosis síndromes mielodisplásicos osteonecrose da arcada osseodentária associada a difosfonatos osteoporose síndrome mielodisplásica Introduction: Medication-related osteonecrosis of the jaw is a frequent collateral effect found in patients under antiresorptive treatments. Malignancies such as multiple myeloma, breast and prostate cancer as well as bone-metabolic disorders such as osteoporosis, lead the indications for these antiresorptive therapies. Even with a low frequency, myelodysplastic syndromes are also entities that have previously been associated with the development of jaw osteonecrosis. Objective: the aim of this study is to present a case of a 78-year-old male patient with myelodysplastic syndrome and secondary osteoporosis, treated with high-dose Zoledronic Acid and who developed a clinical scenario compatible with medication-related osteonecrosis of the jaw during its evolution. Methodology: the case was recorded and treated in the Oral Medicine Department, Facultad de Odontología, Universidad Nacional de Córdoba, during a two-years period with a partial resolution, which recurred fourteen months later, where finally therapeutic success was achieved through a conservative management. Conclusion: Due to the increasingly use of antiresorptive drugs, the development of jaw osteonecrosis is possible associated with less frequent pathologies, such as myelodysplastic syndrome. Treatment success in these patients depends on interdisciplinary management and a rigorous clinical, medical and dental follow-up. Introducción: La osteonecrosis maxilar asociada a medicamentos es una complicación encontrada en pacientes bajo tratamiento con drogas antirresortivas. Patologías oncológicas como mieloma múltiple, cáncer de mama y próstata y alteraciones óseas-metabólicas como la osteoporosis lideran las indicaciones para estas terapias antirresortivas. Aún con una baja frecuencia, los síndromes mielodisplásicos también son entidades que previamente han sido vinculadas al desarrollo de osteonecrosis. Objetivo: el objetivo de este trabajo es presentar un caso de un paciente masculino de 78 años con síndrome mielodisplásico y osteoporosis secundaria, tratado con Ácido Zoledrónico a altas dosis y que en su evolución desarrolló un cuadro clínico compatible con osteonecrosis maxilar asociada a medicamentos. Metodología: el caso fue registrado y tratado en la Cátedra de Estomatología “A” de la Facultad de Odontología, Universidad Nacional de Córdoba, durante un periodo de dos años con una resolución parcial del cuadro, el cual recurrió a los catorce meses, donde finalmente se llegó al éxito terapéutico mediante terapéuticas conservadoras. Conclusión: debido al uso cada vez más extendido de fármacos antirresortivos, es posible el desarrollo de osteonecrosis maxilar asociada a patologías menos frecuentes, como el síndrome mielodisplásico. El éxito del tratamiento en estos pacientes depende del manejo interdisciplinario y de un riguroso seguimiento clínico médico y odontológico. Introdução: Osteonecrose dos maxilares é um efeito colateral frequente em pacientes sob tratamento antirreabsortivo. Doenças malignas, como mieloma múltiplo, câncer de mama e de próstata, bem como distúrbios metabólicos ósseos, como a osteoporose, lideram as indicações dessas terapias anti-reabsortivas. Mesmo com baixa frequência, as síndromes mielodisplásicas também são entidades previamente associadas ao desenvolvimento de osteonecrose mandibular. Objetivo: o objetivo deste estudo é apresentar um caso de paciente do sexo masculino, 78 anos, com síndrome mielodisplásica e osteoporose secundária, tratado com ácido zoledrônico em altas doses e que desenvolveu quadro clínico compatível com osteonecrose de mandíbula associada ao uso de drogas anti-reabsortivas durante sua evolução. Metodologia: o caso foi registrado e tratado no Departamento de Medicina Oral da Facultad de Odontología da Universidad Nacional de Córdoba, durante um período de dois anos com resolução parcial, que se repetiu quatorze meses depois, onde finalmente o sucesso terapêutico foi alcançado através de uma conduta conservadora. Conclusão: Devido ao uso cada vez maior de medicamentos antirreabsortivos, é possível o desenvolvimento de osteonecrose dos maxilares associada a patologias menos frequentes, como a síndrome mielodisplásica. O sucesso do tratamento nesses pacientes depende do manejo interdisciplinar e de um acompanhamento clínico, médico e odontológico rigoroso. Universidad Nacional Cba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2020-12-01 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf text/html https://revistas.unc.edu.ar/index.php/med/article/view/30318 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 77 No. 4 (2020); 373-377 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 77 Núm. 4 (2020); 373-377 Revista da Faculdade de Ciências Médicas de Córdoba; v. 77 n. 4 (2020); 373-377 1853-0605 0014-6722 10.31053/1853.0605.v77.n4 spa https://revistas.unc.edu.ar/index.php/med/article/view/30318/32345 https://revistas.unc.edu.ar/index.php/med/article/view/30318/31322 Derechos de autor 2020 Universidad Nacional de Córdoba http://creativecommons.org/licenses/by-nc/4.0 |